BACKGROUND: Prior research has shown a decrease in medication adherence as dosing
frequency increases; however, meta-analyses have not been able to demonstrate a …

Levodopa is the most effective medication for the treatment of the motor symptoms of
Parkinson's disease. However, over time, the clinical response to levodopa becomes …

Objective L‐dopa is the most widely used and most effective therapy for Parkinson disease
(PD), but chronic treatment is associated with motor complications in the majority of patients …

BACKGROUND: Medication non-adherence is prevalent in Parkinson's disease (PD) and
results in substantial motor dysfunction. Although various approaches have been suggested …

Parkinson's disease (PD) is the second most common neurodegenerative disorder, after
Alzheimer's disease, affecting the elderly worldwide. Current therapy for PD is largely based …

The parkinsonism-hyperpyrexia syndrome (PHS) is a rare but potentially fatal complication
seen in Parkinson's disease (PD) patients, most commonly following reduction or cessation …

Background: In advanced Parkinson disease (PD), immediate-release pramipexole, taken 3
times daily, improves symptoms and quality of life. A once-daily extended-release …

Background The complexity of antiparkinsonian medications makes patients vulnerable to
medication deviations. This study examines the frequency and outcomes of deviations …

Background Levodopa‐carbidopa intestinal gel (LCIG) is administered directly to the small
intestine of patients with advanced Parkinson's disease (APD) to help maintain stable …

Objective: To assess the clinical efficacy of a novel once-daily extended-release (ER)
formulation of the dopamine agonist pramipexole as monotherapy in patients with early …